manfred windisch, Ph.D.
After graduation from the University of Graz in 1985 he spent several years heading a neurobiology group there doing research on brain metabolism and animal model development. Thereafter he was involved for many years in University and industrial research programs in Europe, North America and Asia in the field of neurodegenerative disorders. He established a global network of research collaborations and stimulated intensive scientific information exchange. 1999 he founded the CRO JSW-Lifesciences focusing on the role of alpha and beta-synuclein in pathogenesis of PD and AD. He created and standardized improved transgenic rodent models of neurodegenerative diseases, performing about 60-80 pharmacological studies per year. In parallel he was involved in clinical research in AD, MCI, PD and ALS organizing and conducting so far about 25 international trials from phase 1 to phase 3. The clinical trial experience includes also complex study designs using state of the art imaging techniques and CSF biomarkers.